Drug Discovery World

MAY 1, 2024

A drop in the prices of non-human primates (NHPs) in China indicates a post-pandemic slowdown in Chinese drug development, according to a report in the Financial Times. Data provider Pharmcube reported that investment on new drug discovery in China fell by 32% in 2023 to $4.8 The figures are taken from UBS data.

Vaccine 130

Vaccine Pharmaceuticals Drug Development Research 130

Drug Discovery World

MARCH 13, 2024

According to Statista, revenue in this sector is expected to grow at an annual rate of 6.77%, resulting in a market volume of US$2,208m by 2028 1. Singapore is among a few countries worldwide whose pharmaceutical export value far exceed the import value. UK-based molecular diagnostics group Yourgene operates in Singapore.

Government 173

Government Science Pharmaceuticals Vaccine 173

Drug Discovery World

SEPTEMBER 26, 2022

It’s common knowledge that drug discovery and development is costly, lengthy and has no guarantee of success. It’s why pharmaceutical companies will often spend up to 10 years and upwards of $1 billion before receiving regulatory approval for a drug. Benefits and barriers .

Pharmaceutical Companies 130

Pharmaceutical Companies Drugs Pharmaceuticals Clinical Trials 130

DrugBank

AUGUST 9, 2024

Investment Trends in Pharmaceutical Research and Development Investing in the pharmaceutical sector presents a unique set of challenges and opportunities; let’s examine them in more detail.    The average cost of bringing a new drug to market is about $2.6 trillion by 2028. reported in 2021.

Pharmaceuticals 76

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 76

Codon

SEPTEMBER 29, 2024

2028 Over the next year, the scientific community ferociously interrogated the model. It wasn’t a silver bullet to the hard problem of drug development, but it wasn’t too far off either. 2032 Curiously, the reliance on artificial intelligence in biology did not change typical clinical market dynamics.

Engineering 125

Engineering Virus DNA Therapies 125

Agency IQ

FEBRUARY 2, 2024

This means that the medical device frameworks – including the pre-market pathways and evidentiary requirements, as well as post-market quality system frameworks and reporting requirements – are applied to the vast majority of all (CDRH-regulated) IVD products. IVDs used in blood donation screening/processing). In the E.U.,

FDA 40

FDA Regulations Laboratories Production 40